Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Troriluzole | Obsessive compulsive disorder (OCD) | Phase 3 | Ongoing | Oral | Psychiatric |
| Pfizer Inc. | BAVENCIO (avelumab) | Gastric cancer | Phase 3 | Intravenous | Oncology | |
| Pfizer Inc. | MET-097i - (VESPER-4) | Obesity | Phase 3 | Enrollment Initiation | Oral | Endocrinology |
| Pfizer Inc. | BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 - (BREAKWATER) | BRAF V600E-Mutant Metastatic Colorectal Cancer | Phase 3 | Data Released | Oral | Oncology |
| Pfizer Inc. | IBRANCE (palbociclib) - (PATINA) | HR+, HER2+ Metastatic Breast Cancer | Phase 3 | Data Released | Oral | Oncology |
| Pfizer Inc. | Combined influenza and COVID-19 Vaccine | Vaccine candidate against influenza and COVID-19 | Phase 3 | Data Released | Intramuscular | COVID-19 |
| Pfizer Inc. | Fordadistrogene movaparvovec | Duchenne muscular dystrophy (DMD) | Phase 3 | Data Released | Intravenous infusion | Genetic Disorder |
| Pfizer Inc. | Atirmociclib (PF-07220060) with endocrine therapy (ET) - (TACTIVE-K) | HR+/HER metastatic breast cancer | Phase 3 | Ongoing | Oral | Oncology |
